Bay­er, GSK, No­var­tis and Roche jump­start bio­mark­er can­cer or­ga­ni­za­tion to dri­ve tests for all

A hand­ful of promi­nent on­col­o­gy phar­mas are team­ing up on a next-gen di­ag­nos­tics ini­tia­tive, with the am­bi­tious vi­sion of test­ing for all can­cer pa­tients. Bay­er, Glax­o­SmithK­line, No­var­tis and Roche are lead­ing the Pre­ci­sion Can­cer Con­sor­tium’s dri­ve to open up bio­mark­er test­ing on a glob­al scale.

The new group will try to boost bio­mark­er test­ing in two ways — by in­creas­ing aware­ness about the val­ue of ge­nom­ic test­ing and by work­ing to im­prove ge­nom­ic bio­mark­er test­ing in clin­i­cal tri­als, it said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER